BioRegenx Inc

BioRegenx operates with a negative equity position of -$4.54 million and a debt-to-equity ratio of -0.49, indicating a capital structure dominated by liabilities. The company holds only $69,380 in cash and equivalents, with a current ratio of 0.06, suggesting severe liquidity constraints. Despite a positive operating cash flow of $38,970, the free cash flow is -$1.53 million, reflecting high operational cash outflows. Profitability metrics show a return on equity of 34.02%, but this is misleading due to the negative equity base. The company reported a net loss of $1.54 million and an operating loss of $1.24 million, with a gross profit of $1.50 million, indicating high operating expenses relative to revenue. These results fall below the industry median for profitability metrics, suggesting operational inefficiencies. The company's revenue is concentrated across its subsidiaries, with no disclosed segment breakdown. DocSun, MVHS, and NuLife represent the primary revenue drivers, but the lack of geographic or segment-specific revenue data limits visibility into diversification. The company's exposure to the healthcare services and equipment industry is broad but not well diversified by geography or product line. Outlook data is not available for the current or next fiscal year, but the company's historical revenue of $1.85 million and negative net income suggest a challenging growth trajectory. The company's capital expenditure of -$59,060 indicates a reduction in investment, which may signal a strategic shift or financial constraint. The risk assessment highlights medium liquidity risk and low dilution risk, with a key flag indicating negative net cash after subtracting total debt. The company has not disclosed any dilutive events in recent filings, and the low dilution risk suggests no immediate pressure from share issuance. However, the negative equity position and high debt levels pose significant financial risk. Recent events include the development of the TruScan.Ai mobile app/Website by NuLife and the continued integration of the DocSun AI Engine, which combines ballistocardiography and photoplethysmography technologies. The company has not disclosed any recent regulatory or legal challenges, but the healthcare industry is subject to evolving regulations that could impact operations.